Search Results - "María Ángeles Castro Iglesias"

  • Showing 1 - 7 results of 7
Refine Results
  1. 1
  2. 2

    Efficacy and safety of a two‐drug direct‐acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6 by Lawitz, Eric, Gane, Edward, Feld, Jordan J., Buti, Maria, Foster, Graham R., Rabinovitz, Mordechai, Burnevich, Eduard, Katchman, Helena, Tomasiewicz, Krzysztof, Lahser, Fred, Jackson, Beth, Shaughnessy, Melissa, Klopfer, Stephanie, Yeh, Wendy W., Robertson, Michael N., Hanna, George J., Barr, Eliav, Platt, Heather L., Gordon, Stuart C., Lawitz, Eric J., Ruane, Peter Jerome, Sahota, Amandeep, Terrault, Norah A., Tsai, Naoky, Kalathil, Sumodh C., Reddy, Gautham, Ghesquiere, Wayne, Borgia, Sergio, Conway, Brian, Feld, Jordan, Tsoi, Keith, Cooper, Curtis L., Ghali, Peter Maged, Thompson, Alexander James Venn, Panero, Jose Luis Calleja, Ferret, Sabela Lens Maria Buti, Franinan, Luis Margusino, Angeles Castro Iglesias, Maria, Brown, Ashley, Agarwal, Kaushik, Foster, Graham, Cramp, Matthew, Zuckerman, Eli, Veitsman, Ella, Cohen, Michal, Lurie, Yoav, Ari, Ziv Ben, Janczewska, Ewa, Szymczak, Aleksandra, Halota, Waldemar, Flisiak, Robert, Mahomed, Adam, Sonderup, Mark Wayne, Punt, Zelda Erika, Kgomo, Mpho Klaas, Bernhardi, David C, Burnevich, Eduard Z., Kizhlo, Svetlana

    Published in Journal of viral hepatitis (01-09-2019)
    “…Ruzasvir (MK‐8408, an NS5A inhibitor) and uprifosbuvir (MK‐3682, a nonstructural protein 5B nucleotide inhibitor) are highly potent direct‐acting antiviral…”
    Get full text
    Journal Article
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7

    Peginterferón alfa-2b y Ribavirina en pacientes coinfectados VIH-VHC: eficacia y seguridad en la práctica clínica habitual by López Calvo, S, Castelo Corral, Laura, Pedreira Andrade, José Domingo, Castro Iglesias, María Ángeles, Vázquez Rodríguez, Pilar, Bello Rodríguez, Laura

    Published in Galicia-clinica (2010)
    “…OBJECTIVE: To determine, in routine clinical practice, the efficacy and safety of peginterferon (PEG-IFN) plus ribavirin (RBV) in HCV-HIV co-infected patients…”
    Get full text
    Journal Article